RSM3 TFA
Based on 1 publication(s) in Google Scholar
RSM3 TFA is a METTL3-METTL14 complex inhibitor with a Kd of 3.10 μM for the METTL3-METTL14 complex. RSM3 TFA reduces the m6A modification level of SLC31A1 and the global RNA methylation level. RSM3 TFA upregulates programmed cell death-related genes, enhances cell apoptosis, inhibits pro-cancer signals and suppresses tumor growth. RSM3 TFA is applicable to the research of preeclampsia and cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 98.83%
- 分子式: C130H218N54O26S3.xC2HF3O2
- 分子量:3049.66 (free base)
-
保管条件:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 RSM3 TFA
More
生物活性
RSM3 TFA inhibits the methyltransferase activity of the purified METTL3-METTL14 complex by 45.5%[1].
RSM3 TFA inhibits the viability of CCRF-CEM leukemia cells with an IC50 of 4.6 μM[1].
RSM3 TFA inhibits the viability of DU145 prostate cancer cells with an IC50 of 25.8 μM[1].
RSM3 TFA inhibits the viability of ASPC-1 pancreatic cancer cells with an IC50 of 33.8 μM[1].
RSM3 TFA inhibits the viability of PC3 prostate cancer cells with an IC50 of 26.5 μM[1].
RSM3 (15 μM; 24 h) TFA reduces the migratory capacity of PC3 and DU145 prostate cancer cells[1].
RSM3 (15 μM) TFA induces G1 phase cell cycle arrest and apoptosis in PC3 and DU145 prostate cancer cells[1].
RSM3 (25 μM; 12 h) TFA reduces the protein levels of METTL3 and METTL14 in PC3 prostate cancer cells[1].
RSM3 (25 μM; 12 h) TFA inhibits the activity of the ERK/MAPK signaling pathway in PC3 prostate cancer cells by reducing the phosphorylation level of p42/44[1].
RSM3 (12 h) TFA reduces the global RNA m6A modification level in PC3 and DU145 prostate cancer cells[1].
RSM3 (25 μM; 12 h) TFA induces a specific transcriptomic response in PC3 prostate cancer cells, upregulating programmed cell death, p53 signaling pathway, differentiation and immune pathways, while downregulating cancer proliferation and cell cycle pathways, and enriching gene signatures of apoptosis, p53 and AR pathways[1].
RSM3 (25 μM; 12 h) TFA upregulates NF-κB, inflammation, apoptosis and luminal differentiation-related genes, and downregulates cell cycle, proliferation and stemness-related genes in PC3 prostate cancer cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:PC3 and DU145 (prostate cancer) cells
-
Concentration:15 μM
-
Incubation Time:24 h
-
Result:Resulted in approximately a 2-3 fold reduction in cell migration in PC3 and DU145 cells.
-
Cell Line:PC3 (prostate cancer) cells
-
Concentration:25 μM
-
Incubation Time:12 h
-
Result:Reduced the protein levels of METTL3 and METTL14 in PC3 cells.\n
Reduced phosphorylation levels of p42/44 (ERK1/2).
-
Cell Line:PC3 (prostate cancer) cells
-
Concentration:25 μM
-
Incubation Time:12 h
-
Result:Upregulated NF-kB responsive, inflammatory, apoptosis, and luminal differentiation (AR, PSA, NKX3.1, CK18) genes, and downregulated cell cycle, proliferation, and stemness genes.
RSM3 (20 mg/kg; peritumoral injection; once every 2 days; for 14 consecutive days) TFA inhibits the growth of PC3/ASPC-1 xenografts in mice[1].
RSM3 (50 mg/kg; intraperitoneal injection; daily; 11 days) TFA significantly improves preeclampsia (PE)-related symptoms in rats[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Immunocompromised mice treated PC3 cells (xenograft model)[1]
-
Dosage:20 mg/kg
-
Administration:peri-tumoral injection; every 2 days; 14 days
-
Result:Reduced tumor volumes, average tumor mass.
Decreased METTL3 expression and global m6A levels in tumor tissue.
Increased Caspase-3 expression, decreased Ki67 expression in tumor tissue.
Showed no significant changes in body weight.
Detected no histopathological abnormalities in heart, liver, spleen, lung, or kidney tissue.
-
Animal Model:Immunocompromised mice treated ASPC-1 cells (xenograft model)[1]
-
Dosage:20 mg/kg
-
Administration:peri-tumoral injection; every 2 days; 14 days
-
Result:Reduced tumor volume.
Lowered average tumor mass.
-
Animal Model:Sprague-Dawley (SD) (female, 7-week-old, 200-220 g, PE model)[2]
-
Dosage:50 mg/kg
-
Administration:i.p.; daily; GD 10 to GD 20
-
Result:Significantly reduced systolic blood pressure.
Significantly reduced 24-hour urine protein concentration.
Significantly reduced urine albumin to creatinine ratio.
Significantly lowered placental METTL3 protein expression.
Significantly increased placental SLC31A1 protein expression.
Significantly reduced m6A modification level of SLC31A1 in placental tissue.
化学情報
-
性状 Solid
-
分子量 3049.66 (free base)
-
分子式 C130H218N54O26S3.xC2HF3O2
-
Color White to off-white
-
配列
Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Cys-Met-Glu-Leu-Gly-Arg-Glu-Cys-Leu-Asn-Leu-Trp-NH2 (Stapled between two Cys via bhp)
-
シーケンスの短縮
RRRRRRRRRCMELGRECLNLW-NH2 (Stapled between two Cys via bhp)
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Placenta
METTL3 suppressing SLC31A1 m6A modification regulates trophoblast migration and invasion. [Abstract]2025 May 2:164:21-30. PMID: 40088504
溶剤 & 溶解度
DMSO : 66.67 mg/mL (Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
純度とドキュメンテーション
-
データシート (290 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
取扱説明書 (2659 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
RSM3 TFA 関連分類
HY-P10387A 関連分類
Powered by Bioz